XTL Biopharmaceuticals Ltd.
Support and Resistance Levels
Past performance
News About XTLB
All events for XTLB
All deals for XTLB
Financial Ratios
Financial Statements
XTLB vs Sector & Peers
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel. Website xtlbio.com
Headquarters Ramat Gan, TA, IL